Literature DB >> 16714368

Molecular analysis of the IVS8-T splice variant 5T and M470V exon 10 missense polymorphism in Iranian males with congenital bilateral absence of the vas deferens.

Ramin Radpour1, Mohamad Ali Sadighi Gilani, Hamid Gourabi, Ahmad Vosough Dizaj, Sepideh Mollamohamadi.   

Abstract

Congenital bilateral absence of the vas deferens (CBAVD) is responsible for 2-6% of male infertility in which mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have been identified. To investigate CBAVD at the molecular level in Iran, we have characterized the mutations in the CFTR gene in 106 patients with this condition. None had clinical manifestations of cystic fibrosis (CF). We also analysed a DNA variant (the 5T allele) in a noncoding region of CFTR, which causes reduced levels of the normal CFTR protein and M470V exon 10 missense polymorphism. Five of the 106 patients with CBAVD had mutations in both copies of the CFTR gene, and none of them had the 5T allele. Eighty-five patients had a mutation in at least one copy of CFTR, and of these patients, 46 had one 5T allele (in 11 cases, two alleles and in 35 cases, just one allele of 5T was detected). In 21 patients, no CFTR and 5T mutations were found (19.81%). 5T/M470 genotype was found in 19 patients, 5T/V470 was found in 3 and 5T with heterozygote form of M470V was found in 24 CBAVD patients. In CBAVD patients, 28 F508del carriers were identified. Most of our patients with CBAVD have mutations in the CFTR gene. The combination of the 5T allele in one copy of the CFTR gene with a CF mutation in the other copy is the most common cause of CBAVD in Iran. The 5T allele mutation has a wide range of clinical presentations and revealed a high frequency, occurring in patients with CBAVD or moderate forms of CF and infertile men.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714368     DOI: 10.1093/molehr/gal046

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  7 in total

1.  The CFTR polymorphisms poly-T, TG-repeats and M470V in Chinese males with congenital bilateral absence of the vas deferens.

Authors:  Wu-Hua Ni; Lei Jiang; Qian-Jin Fei; Jian-Yuan Jin; Xu Yang; Xue-Feng Huang
Journal:  Asian J Androl       Date:  2012-07-30       Impact factor: 3.285

2.  Cystic fibrosis transmembrane conductance regulator-related male infertility: Relevance of genetic testing & counselling in Indian population.

Authors:  Avinash Gaikwad; Shagufta Khan; Seema Kadam; Rupin Shah; Vijay Kulkarni; Rangaswamy Kumaraswamy; Kaushiki Kadam; Vikas Dighe; Rahul Gajbhiye
Journal:  Indian J Med Res       Date:  2020-12       Impact factor: 2.375

3.  The susceptibility of T5-TG12 of the CFTR gene in chronic bronchitis occurrence in a Chinese population in Jiangsu province, China.

Authors:  Ping Wang; Satoru Naruse; Hong Yin; Zhongfang Yu; Tianqu Zhuang; Wei Ding; Yanmin Wu; Muxin Wei
Journal:  J Biomed Res       Date:  2012-04-22

4.  The CFTR M470V, intron 8 poly-T, and 8 TG-repeats detection in Chinese males with congenital bilateral absence of the vas deferens.

Authors:  Qiang Du; Zheng Li; Yongfeng Pan; Xiaoliang Liu; Bochen Pan; Bin Wu
Journal:  Biomed Res Int       Date:  2014-01-08       Impact factor: 3.411

5.  Exon 10 CFTR gene mutation in male infertility.

Authors:  Zohreh Hojati; Somaye Heidari; Majid Motovali-Bashi
Journal:  Iran J Reprod Med       Date:  2012-07

Review 6.  Basic and clinical genetic studies on male infertility in Iran during 2000-2016: A review.

Authors:  Sahar Moghbelinejad; Hossein Mozdarani; Pegah Ghoraeian; Reihaneh Asadi
Journal:  Int J Reprod Biomed       Date:  2018-03

Review 7.  Mutations of the cystic fibrosis transmembrane conductance regulator gene in males with congenital bilateral absence of the vas deferens: Reproductive implications and genetic counseling (Review).

Authors:  Xiangrong Cui; Xueqing Wu; Qiang Li; Xuan Jing
Journal:  Mol Med Rep       Date:  2020-08-24       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.